Fluoroquinolone drugs are frequently and globally prescribed as a measure to cure bacterial infections in humans and animals. There is an extensive list of drugs in this class, but the most familiar are name brands Cipro, Levaquin (now off market), Avelox, and their generics ciprofloxacin, levofloxacin, and moxifloxacin. These antibiotics have shown to inhibit DNA replication much like chemotherapy. Since May 12, 2016, The Food & Drug Administration advises that fluoroquinolone antibiotics should be reserved for medical conditions only when no other options exist. In FDA and European Medicines Agency black box warnings over the last few years, they have indicated fluoroquinolones have been associated with disabling and potentially irreversible, serious adverse reactions within different body systems that can occur simultaneously to cause damage affecting: central nervous system, musculoskeletal, visual and renal systems; tendon disorders and spontaneous ruptures; systemic peripheral neuropathy; psychosis; aortic aneurysm; diabetes/hypoglycemia; hepatotoxicity; cytochrome P450 (CYP450).
Scientific work from Finland indicates the potential of permanent mitochondria damage[1]. Mitochondrial dysfunction carries with it an extensive list of illnesses ranging from chronic fatigue to serious disease such as dementia, Parkinson’s and cancers to name just a few.
Overuse of these potent antibiotics for conditions like sinus, urinary tract and ear infections has been linked to the development of antibiotic resistant infections, which will result in the dire inability to treat emerging bacterial mutations. Most people are unaware that fluoroquinolones are used in surgical procedures via IV, Lasik, cataract surgery, and given for prophylactic measures. The general population and medical community also remain largely uninformed of the growing global epidemic of people experiencing severe ADR’s (adverse drug reaction) in conjunction with extensive, simultaneous medical issues which receive inaccurate or no proper diagnosis.